The mammalian epidermis provides an essential permeability barrier that limits fluid loss to the surrounding environment and prevents bacteria, fungi, toxic compounds and allergens from entering the body. The epidermis is a stratified epithelium, in which epidermal keratinocytes arise from proliferating basal cells and move outwards through a series of distinct differentiation events to form the stratum corneum. This is a two-compartment structure that consists of a lipidenriched extracellular matrix, in which an interlocking meshwork of terminally differentiated corneocytes are embedded. Epidermal differentiation culminates with the shedding (desquamation) of the outermost layer of corneocytes, which is essential to control the thickness of the stratum corneum. Desquamation is accomplished by the physical degradation of adhesions between corneocytes (corneodesmosomes) in a tightly regulated proteolytic process. Members of the kallikrein subfamily of trypsin-like serine proteases, including kallikrein-related peptidase 5 and kallikrein-related peptidase 7, have been implicated in the degradation of corneodesmosomal proteins during desquamation [1] [2] [3] [4] [5] [6] [7] [8] [9] .
A r t i c l e s thereby causing shedding of the entire stratum corneum and loss of the epidermal barrier. The increased epidermal kallikrein activity in the lower layers of the epidermis might also trigger an inflammatory cascade through the activation of a protease activated receptor (PAR)-2-NFκB pathway 20 , and further impair barrier formation by degrading the lipid hydrolases that manufacture stratum corneumspecific lipids 21 .
The molecular mechanisms that initiate the proteolytic activation of epidermal pro-kallikreins in the granular layer are not well understood. Pro-kallikrein-related peptidase 5 has been shown to undergo auto-activation after extended periods (>5 h) of incubation at 37 °C, and this has led to the proposal that an epidermal pro-kallikrein activation cascade with kallikrein-related peptidase 5 at the apex and involving pro-kallikrein-related peptidase 7 mediates physiological desquamation 22 . This cascade could also be responsible for activation of pro-kallikrein in the granular layer in Netherton syndrome or, alternatively, pro-kallikreins could be activated by other proteases expressed in the granular layer.
Matriptase is a transmembrane serine protease that is very unusual for a trypsin-like serine protease in that it undergoes efficient autoactivation, and therefore has the capacity to initiate proteolytic cascade reactions 23, 24 . In this respect, matriptase is similar to the closely related enteropeptidase, which is the physiological initiator of the digestive enzyme activation cascade 25 . This prompted us to investigate whether activation of pro-kallikreins by matriptase contributes to the aberrant proteolytic activity associated with Netherton syndrome. By using a biochemical approach, as well as taking advantage of the faithful replication of all the key features of Netherton syndrome in LEKTI-deficient mice [4] [5] [6] 20 , we now show that matriptase is an efficient activator of epidermal pro-kallikreins that co-localize with LEKTI at the granular-transitional layer boundary where epidermal separation takes place in Netherton syndrome. Furthermore, we show that all the central manifestations of Netherton syndrome in LEKTIdeficient mice, such as aberrant proteolytic activity in the lower epidermis, corneodesmosome fragility, stratum corneum loss and skin inflammation, depend on the epidermal expression of matriptase. Our findings increase the molecular understanding of epidermal desquamation and its deregulation in Netherton syndrome, and define a matriptase-pro-kallikrein activation pathway that might operate in a variety of physiological and pathological processes.
RESULTS

Matriptase and LEKTI co-localize in the epidermis
We first determined the localization of LEKTI and matriptase in normal mouse epidermis by combining LEKTI immunostaining with X-gal staining of sections from a mouse strain (St14 +/E16β-gal ) 26 that carries one wild-type St14 allele and one allele in which the St14 exons that encode the serine protease domain of matriptase were replaced by a promoterless β-galactosidase marker gene (Fig. 1) . This analysis showed that matriptase was expressed in the suprabasal epidermis with the highest level of expression in the granular and transitional cell layers (Fig. 1a) and that matriptase co-localized with LEKTI (Fig. 1b,c) . The specificity of the detection procedure was demonstrated by the absence of β-galactosidase activity in the epidermis of wild-type mice (Fig. 1d) , and by the lack of immunoreactivity in Spink5 −/− epidermis (Fig. 1e) .
Matriptase activates epidermal pro-kallikreins
Epidermal kallikreins are all synthesized as inactive pro-enzymes that require proteolytic activation by cleavage after a basic amino acid residue (Arg or Lys) that is located in a highly conserved activation motif preceding the catalytic domain. The ability of matriptase to undergo efficient auto-activation, its previously established capacity to initiate proteolytic cascades 27, 28 , its specific cleavage of proteins after Arg or Lys residues, its co-expression with LEKTI in epidermis ( Fig. 1) and its unaltered expression in LEKTI-deficient suprabasal epidermis ( Supplementary Fig. 1 ) made matriptase a prime candidate for the activation of epidermal pro-kallikreins and the generation of aberrant epidermal kallikrein activity in the absence of LEKTI. To test this hypothesis, we expressed His-tagged versions of the two main epidermal pro-kallikreins, pro-kallikrein-related peptidase 5 and pro-kallikrein-related peptidase 7, in HEK-293T cells, and purified them from serum-free conditioned medium using metal chelation affinity chromatography (Fig. 2a) . Recombinant pro-kallikreinrelated peptidase 5 appeared as a single band with a molecular weight of 40 kDa and with the expected molecular weight of 32 kDa after deglycosylation (Fig. 2a) . Pro-kallikrein-related peptidase 7 appeared as two bands: one with a molecular weight of 28 kDa, as expected for unglycosylated pro-kallikrein-related peptidase 7, and a second, higher molecular weight 34-kDa band (Fig. 2a) . Only the 28-kDa band remained after pretreatment of the preparation with a combination of N-glycosidase F, O-glycosidase and α-2(3,6,8,9) neuraminidase, showing that the two bands represent different glycosylation forms of pro-kallikrein-related peptidase 7 (Fig. 2a) . In agreement with previous studies 22 , the incubation of 50 nM pro-kallikreinrelated peptidase 5 or pro-kallikrein-related peptidase 7 for 15 or 30 min at 37 °C resulted in very low kallikrein activity, as determined by the ability to hydrolyze the kallikrein-selective fluorogenic substrate Boc-Val-Pro-Arg-AMC (Fig. 2b,c) . However, incubation of either of the two pro-kallikrein-related peptidases with catalytic amounts of matriptase (2.5 nM, 20-fold lower concentration than that of the pro-kallikrein-related peptidases) under identical reaction conditions resulted in the time-dependent conversion of both pro-kallikrein 5 and 7 to their proteolytically active forms, which could hydrolyze the A r t i c l e s fluorogenic substrate (Fig. 2b,c) . As described 22 , kallikrein-related peptidase 5 could activate pro-kallikrein-related peptidase 5 and prokallikrein-related peptidase 7 (Fig. 2d,e) under identical reaction conditions. Together, these data show that the auto-activating serine protease, matriptase, can activate epidermal pro-kallikreins, which do not undergo efficient auto-activation. Once converted to its active form, kallikrein-related peptidase 5 can proteolytically activate prokallikrein-related peptidase 5 and pro-kallikrein-related peptidase 7, in line with the previously proposed role of this protease in the propagation of an epidermal pro-kallikrein-related peptidase cascade. Prostasin is a GPI-anchored serine protease that is proteolytically activated by matriptase during terminal epidermal differentiation and is found only as a pro-enzyme in matriptase-deficient human and rodent epidermis 27, 29 . As prostasin was a poor activator of prokallikrein-related peptidase 5 and pro-kallikrein-related peptidase 7, even when incubated in up to a 50-fold molar excess ( Supplementary   Fig. 2 ), we concluded that it does not serve as an activator of epidermal pro-kallikreins in normal or LEKTI-deficient epidermis.
The co-localization of matriptase and LEKTI at the site of stratum corneum separation in Netherton syndrome suggested that not only kallikreins, but also matriptase, could be a direct target for LEKTI 30 and that increased matriptase proteolytic activity could contribute to excess corneodesmosome degradation in Netherton syndrome, independent of pro-kallikrein activation. To investigate this notion, we tested the capacity of LEKTI to inhibit matriptase in a purified system (Fig. 3) . All functionally active inhibitory domains of LEKTI (domains 2-15) were generated as six recombinant GST fusion proteins using an Escherichia coli strain that is permissive for disulfide bond formation and were purified by affinity chromatography as described (Fig. 3a) . GST alone did not inhibit any of the proteases tested (data not shown). However, each of the six recombinant LEKTI-GST fusion proteins was biologically active, as shown by their ability to inhibit recombinant kallikrein-related peptidase 5 in a fluorogenic peptide hydrolysis assay (Fig. 3b) .
None of the six LEKTI-GST fusion proteins showed any inhibitory activity toward matriptase in a similar assay when tested in up to 800-fold molar excess of the protease, whereas the activity of the membrane protease could be completely inhibited by its cognate inhibitor, hepatocyte growth factor activator inhibitor-1 (HAI-1; Fig. 3c ). We next incubated purified recombinant prostasin with the six recombinant LEKTI-GST fusion proteins and performed a fluorogenic peptide substrate assay to determine whether prostasin was susceptible to LEKTI inhibition. Whereas the cognate inhibitor of prostasin, protease nexin-1 (PN-1) 31 , completely abolished peptide substrate hydrolysis, none of the six recombinant LEKTI-GST fusion proteins showed any detectable inhibitory activity toward this protease (Fig. 3d) . Together, these data show that neither matriptase nor prostasin are direct inhibitory targets for LEKTI.
Matriptase ablation eliminates aberrant protease activity
The efficient activation of epidermal pro-kallikreins by matriptase, when combined with the specific expression of the protease at the boundary between the granular and transitional cell layers, and the previously established ability of matriptase to undergo autoactivation all suggested that matriptase could initiate a 'run-away' epidermal kallikrein cascade in Netherton syndrome. To investigate this idea, we took advantage of a previously developed LEKTIdeficient Spink5 −/− mouse strain, which emulates the central features of Netherton syndrome, including separation of the stratum corneum at the granular-transitional layer boundary, loss of epidermal barrier function and severe skin inflammation [4] [5] [6] 20 . A key feature of LEKTIdeficient epidermis is the aberrant proteolytic activity in the lower layers of the epidermis that can be revealed by in situ zymography 4, 11 .
We therefore studied serine protease activity in the epidermis of normal and LEKTI-deficient skin in situ by overlaying skin sections with a quenched fluorescent casein substrate (Fig. 4) .
As described in previous studies 7 , caseinolytic activity was predominantly confined to the upper stratum corneum of normal skin (Fig. 4a-c) and most of this caseinolytic activity was blocked by pre-incubation of the epidermal sections with recombinant LEKTI (Supplementary Fig. 3 ). By contrast, LEKTI-deficient epidermis showed strong caseinolytic activity throughout the epidermis (Fig. 4d-f) . There was also a marked increase in caseinolytic activity in the underlying dermis of LEKTI-deficient mice (Fig. 4d-f and data not shown). This increase in dermal proteolytic activity after LEKTI ablation has not been described previously, but was reproducible in multiple independent experiments. It probably reflects the influx of protease-laden inflammatory cells into the dermis and basal epidermal layers caused by loss of the stratum corneum as well as hyperactivation of a PAR-2 inflammatory pathway by epidermal kallikreins 20 (see below). Caseinolytic activity in matriptase-deficient epidermis was similar in location and intensity to that of normal epidermis, showing that epidermal kallikrein activation and activity in the upper layer of the stratum corneum is retained in the absence of matriptase (Fig. 4g-i) . However, the genetic elimination of matriptase completely abolished the aberrant caseinolytic activity that was caused by LEKTI deficiency in both the lower epidermal layers and the dermis (Fig. 4j-l) . Indeed, the sites of expression of caseinolytic activity of LEKTI/matriptase double-deficient epidermis were identical to those seen in normal and matriptase-deficient epidermis in being restricted to the upper layers of the stratum corneum (Fig. 4j-l) . 
A r t i c l e s
Matriptase elimination improves stratum corneum function As previously described, the epidermis of newborn LEKTIdeficient mice mimicked the epidermis of babies with Netherton syndrome in that there was extensive loss of the stratum corneum (Fig. 5a,b) . Compatible with the idea that matriptase has a key role in premature activation of pro-kallikreins, the ablation of matriptase from LEKTI-deficient epidermis prevented spontaneous loss of the stratum corneum ( Fig. 5b-d) , and epidermis lacking both LEKTI and matriptase was outwardly indistinguishable from matriptasedeficient epidermis (Fig. 5c,d) . Loss of the stratum corneum in LEKTI-deficient skin was caused by separation of the epidermis at the granular-transitional cell layer boundary, and led to the direct exposure of the living layers of the epidermis to the external environment (Fig. 5e,f) . However, we found no epidermal separation at the granular-transitional cell layer boundary in epidermis lacking both LEKTI and matriptase ( Fig. 5f-h) , which was histologically indistinguishable from matriptase-deficient epidermis (Fig. 5g,h) . Elimination of matriptase from LEKTI-deficient epidermis also restored keratohyalin granules in the upper epidermis ( Fig. 5f-h ) that contained profilaggrin, as determined by immunofluorescence ( Supplementary Fig. 4) . Furthermore, loss of matriptase prevented the accelerated processing of profilaggrin that is characteristic of LEKTI-deficient human and mouse epidermis, supporting the idea external environment, confirming that corneodesmosome integrity in the lower layers is compromised by the loss of LEKTI (Fig. 6c,d ).
As expected, tape stripping of matriptase-deficient epidermis did not lead to complete removal of the stratum corneum (Fig. 6e,f) . However, the lower stratum corneum also remained intact in LEKTI-deficient epidermis from which matriptase had also been ablated (Fig. 6g,h) , which shows that corneodesmosome integrity was restored in lower levels of the epidermis and confirms that matriptase ablation eliminates the aberrant protease activity in LEKTI-deficient epidermis. These data suggest that kallikrein proteolytic activity resulting from auto-activation of kallikrein-related peptidase 5 and kallikrein-related peptidase 5-mediated activation of kallikreinrelated peptidase 7 is not sufficient to cause premature desquamation of LEKTI-deficient epidermis.
Matriptase loss prevents kallikrein-mediated inflammation
The absence of LEKTI not only causes premature shedding of the stratum corneum, but also causes the activation of pro-inflammatory pathways by kallikrein related peptidase 5-mediated activation of a PAR-2-NFκB axis 20 in the granular layer of the epidermis. The requirement of matriptase for aberrant protease activity in LEKTIdeficient dermis and epidermis (Fig. 4) led us to investigate whether the activation of this kallikrein-PAR-2-NFκB pro-inflammatory that matriptase acts upstream of epidermal kallikreins ( Supplementary Fig. 4) . As well as improving the outward and histological appearance of the skin, the elimination of matriptase also led to a functional improvement in LEKTI-deficient epidermis in an established assay of inward-out epidermal barrier function (Fig. 5i) . Thus, although loss of matriptase by itself impairs epidermal barrier function by weakening epidermal tight junctions 32 and by preventing calpain/ caspase-14/bleomycin hydrolase-mediated profilaggrin/filaggrin processing [33] [34] [35] , the ablation of the serine protease markedly improved, rather than further impaired, the barrier function of LEKTI-deficient epidermis. Together, these data show that the expression of these key features of Netherton syndrome in the LEKTI-deficient mouse model depends on matriptase.
Loss of matriptase restores corneodesmosome integrity
Corneodesmosome integrity can be assessed by a tape stripping procedure in which adhesive-coated discs are repeatedly applied to the same area of the skin, which then is subjected to histological analysis 36, 37 . Subjection of normal epidermis to repeated tape stripping led to the removal of most of the stratum corneum (Fig. 6a,b) . However, a layer of stratum corneum remained, and the granular layer was never exposed (Fig. 6b) . By contrast, when LEKTI-deficient epidermis was subjected to the same procedure, the entire stratum corneum was removed, and living keratinocytes in the granular layer of the epidermis were directly exposed to the pathway was also dependent on the expression of matriptase. Specifically, we determined the levels of mRNA for tumor necrosis factor-α, interferon-γ, interleukin (Il)-1β and Il-6 in LEKTI-deficient skin that was either sufficient or deficient in matriptase (Fig. 7) . In agreement with previous studies of Netherton syndrome and LEKTIdeficient mouse skin, the loss of LEKTI markedly increased the expression of all four cytokines. The absence of matriptase greatly reduced inflammatory cytokine expression in LEKTI-deficient skin, with levels of the four cytokines being comparable to those found in normal or matriptase-deficient skin. We also examined the Netherton allergy/atopy-associated Th2 and Th17 cytokines Il-4, Il-13 and Il-17, in LEKTI-deficient skin that was either sufficient or deficient in matriptase (Fig. 7) . The absence of matriptase greatly reduced Il-13 expression in LEKTI-deficient skin, with levels of Il-13 being comparable to those found in normal or matriptase-deficient skin. Il-4 and Il-17 mRNA expression was undetectable in the epidermis of mice of any genotype (data not shown).
In summary, this study shows that the absence of LEKTI at the granular-transitional cell boundary leads to a run-away kallikrein proteolytic cascade, which is initiated by and depends on matriptase. This causes premature corneodesmosome degradation, loss of the stratum corneum, and the activation of epidermal pro-inflammatory pathways characteristic of Netherton syndrome.
DISCUSSION
Studies conducted over the last two decades have yielded new insights into the process of terminal epidermal differentiation of the mammalian epidermis, including the molecular mechanisms that regulate stratum corneum thickness through the desquamation of the uppermost epidermal layers 30 . This research was pioneered by Egelrud and colleagues, who first described the abundant expression of a set of epidermis-specific kallikreins in the stratum corneum and showed that they could degrade corneodesmosomal proteins, the key step of epidermal desquamation [1] [2] [3] . A second decisive advance was the identification of the deficiency of the serine protease inhibitor LEKTI as the cause of Netherton syndrome 13 .
The subsequent generation and analysis of LEKTI-deficient mouse models of Netherton syndrome, complemented by biochemical studies, revealed that epidermal kallikreins are direct inhibitory targets for LEKTI [4] [5] [6] . These studies also showed that the stability of LEKTI-kallikrein inhibitory complexes is pH-dependent, and that the complexes dissociate in the acidic environment of the upper stratum corneum, thereby restricting kallikrein activity and, thus, desquamation, to the uppermost layers of the stratum corneum 7 . Epidermal kallikreins are synthesized as catalytically inactive zymogens, incapable of degrading corneodesmosomes in either normal or LEKTIdeficient epidermis. Our current study expands on these advances by showing that the auto-activating membrane protease, matriptase, prematurely activates epidermal pro-kallikreins and thereby contributes to premature desquamation at the granular-transitional cell layer boundary. We also provide evidence that matriptase-dependent pro-kallikrein activation is at least partly responsible for immunological aspects of the syndrome by showing that the increased expression of key A r t i c l e s pro-inflammatory cytokines, including the Th2 cytokine, IL-13, in LEKTI-deficient epidermis, also depends on matriptase. Our findings suggest a strategy for treatment of the disease. Several small and large molecule inhibitors with high specificity for matriptase are in pre-clinical development 38 , and these might be able to partially inhibit matriptase and thereby to restore homeostasis of LEKTIdeficient epidermis. It remains to be established whether the matriptase-prokallikrein cascade defined here contributes not only to the pathologic proteolysis in Netherton syndrome, but also to normal desquamation of homeostatic epidermis and other stratified epithelia. The impairment of desquamation of matriptase-deficient human and mouse epidermis 29, 33 provides evidence that it does. Arguing against this, however, is our finding that in situ proteolytic activity in the upper layers of matriptase-deficient and combined LEKTI and matriptase-deficient stratum corneum is relatively unaltered. Prolonged incubation of pro-kallikrein-related peptidase 5 (>5 h) at body temperature causes its auto-activation, and kallikrein-related peptidase 5 can activate pro-kallikrein-related peptidase 7 at a slow rate 22 . Furthermore, other kallikreins, including kallikreinrelated peptidases 1, 6, 8, 13 and 14, are expressed in the epidermis. It is therefore likely that the micro-environment within the upper epidermis could favor pro-kallikrein auto-activation and a prokallikrein activation cascade, as proposed previously 9, 22, 39, 40 and that desquamation is therefore only modestly impaired in the upper stratum corneum of matriptase-deficient epidermis 33 . It is important to note that although matriptase-deficient and combined LEKTI and matriptase-deficient epidermis were indistinguishable in their outward and microscopic appearance, epidermal proteolytic activity and corneodesmosome integrity, they were not exact phenocopies as regards the rate of transepidermal fluid loss. This indicates that either some low level of residual pro-kallikrein activation takes place at the granular-transitional layer (although this was undetectable by in situ zymography) or that there are additional, as yet undefined, molecular pathways (intrinsic to the skin or systemic) besides premature epidermal pro-kallikrein activity that contribute to the pathogenesis of Netherton syndrome.
Besides providing molecular insights into the pathogenesis of Netherton syndrome, the current study might also be relevant for the understanding of common epidermal/immune disorders. Lossof-function mutations in the FLG gene, which encodes profilaggrin, are extremely frequent in some populations, and homozygosity or heterozygosity for loss-of-function FLG alleles causes the common semi-dominant skin condition ichthyosis vulgaris and is a predisposing factor in atopic eczema and asthma 41, 42 . Clearly, the level of epidermal filaggrin is central to these diseases, and our demonstration that a matriptase-prokallikrein pathway regulates the rate of processing of profilaggrin to filaggrin suggests that genetic or environmentally induced perturbations in the activity of this proteolytic pathway might represent additional predisposing factors for these common disorders. Furthermore, dysregulated kallikrein proteolytic activity has been proposed to be involved not only in skin and inflammatory diseases, but also in cancer 43, 44 . Matriptase is widely expressed in epithelial tissues and is also expressed by certain leukocyte populations, including monocytoid cells and mast cells 28, 45, 46 . Notably, spatial dysregulation of matriptase suffices to initiate both chronic inflammation and epithelial neoplasia 47 . It is therefore plausible, if not likely, that the matriptase-pro-kallikrein activation cascade identified in this study might be relevant to the pathogenesis of additional inflammatory, autoimmune and proliferative diseases.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
